ResearcherErciyes UniversityNo recent work listed
Velı Berk
Matched on OpenAlex author ID A5044883162. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2012: 3 papers · 2013: none · 2014: none · 2015: 1 paper
Papers 4
- Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of M… Co-author DOI 10.5114/wo.2014.43933↗
- XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Co-author DOI 10.5754/hge12181↗
- Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Med… Co-author DOI 10.7314/apjcp.2012.13.5.1841↗
- Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multic… Co-author PMID 22517701↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ali̇ İnal · 4 shared papers, 2012–2015 · strength 0.12
- Paper Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a m… DOI 10.5114/wo.2014.43933↗
- Paper XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. DOI 10.5754/hge12181↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Fahriye Tuğba Köş · 3 shared papers, 2012–2015 · strength 0.10
- Paper Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a m… DOI 10.5114/wo.2014.43933↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Abdurrahman Işıkdoğan · 3 shared papers, 2012–2015 · strength 0.10
- Paper Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a m… DOI 10.5114/wo.2014.43933↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Nuriye Özdemir · 3 shared papers, 2012 · strength 0.08
- Paper XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. DOI 10.5754/hge12181↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Metin Özkan · 3 shared papers, 2012 · strength 0.08
- Paper XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. DOI 10.5754/hge12181↗
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Mahmut Gümüş · 2 shared papers, 2012 · strength 0.05
- Paper Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective… DOI 10.7314/apjcp.2012.13.5.1841↗
- Paper Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cispl… PMID 22517701↗
- Olçun Ümit Ünal · 1 shared paper, 2012 · strength 0.03
- Özlem Sönmez · 1 shared paper, 2012 · strength 0.03
- Gamze Göksel · 1 shared paper, 2012 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.